Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is the third leading cause of tumor-related mortality worldwide. In recent years, the emergency of immune checkpoint inhibitor (ICI) has revolutionized the management of HCC. Especially, the combination of atezolizumab (anti-PD1) and bevacizumab (anti-VEGF) has been approved by the FDA as the first-line treatment for advanced HCC. Despite great breakthrough in systemic therapy, HCC continues to portend a poor prognosis owing to drug resistance and frequent recurrence. The tumor microenvironment (TME) of HCC is a complex and structured mixture characterized by abnormal angiogenesis, chronic inflammation, and dysregulated extracellular matrix (ECM) remodeling, collectively contributing to the immunosuppressive milieu that in turn prompts HCC proliferation, invasion, and metastasis. The tumor microenvironment coexists and interacts with various immune cells to maintain the development of HCC. It is widely accepted that a dysfunctional tumor-immune ecosystem can lead to the failure of immune surveillance. The immunosuppressive TME is an external cause for immune evasion in HCC consisting of 1) immunosuppressive cells; 2) co-inhibitory signals; 3) soluble cytokines and signaling cascades; 4) metabolically hostile tumor microenvironment; 5) the gut microbiota that affects the immune microenvironment. Importantly, the effectiveness of immunotherapy largely depends on the tumor immune microenvironment (TIME). Also, the gut microbiota and metabolism profoundly affect the immune microenvironment. Understanding how TME affects HCC development and progression will contribute to better preventing HCC-specific immune evasion and overcoming resistance to already developed therapies. In this review, we mainly introduce immune evasion of HCC underlying the role of immune microenvironment, describe the dynamic interaction of immune microenvironment with dysfunctional metabolism and the gut microbiome, and propose therapeutic strategies to manipulate the TME in favor of more effective immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · cited 1×
“Since the first tyrosine kinase inhibitor (TKI) sorafenib was proven to extend the survival in advanced HCC patients without compromising liver function in 2008 (5), multi-TKIs and vascular endothelial growth factor (VEGF) inhibitors have been integrated into standard systemic therapy for advanced HCC (6–9).”
BackgroundEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“The tumor microenvironment is a complex ecosystem that plays an indispensable role from cancer initiation to distant metastasis (11).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Introduction to the human gut microbiota
Thursby, E., & Juge, N. (2017) · Biochemical Journal · doi:10.1042/bcj20160510 · Cited by 3,600
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · cited 2×
“Liver tumor cells and stromal cells express corresponding ligands to evade anti-tumor immunity (88).”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
The impact of diet and lifestyle on gut microbiota and human health
Conlon, M., & Bird, A. (2014) · Nutrients · doi:10.3390/nu7010017 · Cited by 1,567
Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538 · cited 1×
“Non-parenchymal cells and infiltrating immune cells could secrete several cytokines and concurrently keep sensitive to these cytokines (108, 109).”
BackgroundGut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Gur, C., Ibrahim, Y., Isaacson, B., Yamin, R., Abed, J., Gamliel, M., Enk, J., Bar-On, Y., Stanietsky-Kaynan, N., Coppenhagen-Glazer, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.010 · Cited by 1,490
The gut-liver axis and the intersection with the microbiome
Tripathi, A., Debelius, J., Brenner, D. A., Karin, M., Loomba, R., Schnabl, B., & Knight, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0011-z · Cited by 1,480
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246
Self-citationEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076 · cited 5×
“Secretion of TGF-b, IL-10, and VEGF into the TME all contributes to immunosuppression (42).”
BackgroundInfluentialHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Chinese Human Proteome Project (CNHPP) Consortium, Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., et al. (2019) · Nature · doi:10.1038/s41586-019-0987-8 · Cited by 947
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912 · cited 1×
“In a mouse model of HCC, CTNNB1 mutation or activation of WNT-b-catenin pathway could downregulate CCL5 expression and dampen DC recruitment, leading to immune escape and resistance to anti-PD-1 therapy (128).”
BackgroundKuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.102 · Cited by 897 · cited 2×
“Mechanistically, CD4 CD25 FoxP3 Treg cells could damage CD8 T cell cytotoxicity by reducing the release of granzyme A, B, and perforin (57).”
BackgroundNakaya, M., Xiao, Y., Zhou, X., Chang, J.-H., Chang, M., Cheng, X., Blonska, M., Lin, X., & Sun, S.-C. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.007 · Cited by 866
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Self-citationZhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y.-X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319664 · Cited by 841
Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
Haas, R., Smith, J., Rocher-Ros, V., Nadkarni, S., Montero-Melendez, T., D’Acquisto, F., Bland, E. J., Bombardieri, M., Pitzalis, C., Perretti, M., et al. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002202 · Cited by 774
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719 · cited 1×
“Focal gains at chromosome 6p21 leads to overexpression of VEGFA and thereby foster an immunosuppressive TME (126, 127).”
BackgroundTumor Immunotherapy Directed at PD-1
Ribas, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1205943 · Cited by 683
Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., Simeone, D. M., Zou, W., & Welling, T. H. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.039 · Cited by 675
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F., & Korangy, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3232 · Cited by 642
Cancer SLC43A2 alters T cell methionine metabolism and histone methylation
Bian, Y., Li, W., Kremer, D. M., Sajjakulnukit, P., Li, S., Crespo, J., Nwosu, Z. C., Zhang, L., Czerwonka, A., Pawłowska, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2682-1 · Cited by 642
Diverging inflammasome signals in tumorigenesis and potential targeting
Karki, R., & Kanneganti, T.-D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., Ezoe, S., Kanakura, Y., Sato, E., Fukumori, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316796110 · Cited by 627
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice
Li, J., Sung, C. Y. J., Lee, N., Ni, Y., Pihlajamäki, J., Panagiotou, G., & El-Nezami, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518189113 · Cited by 626
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., et al. (2021) · Nature · doi:10.1038/s41586-021-04003-2 · Cited by 619
Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609 · cited 1×
“However, once the tumor is initiated and developed, they would lose the ability of differentiation and cause inhibition of NK cell responses (46).”
BackgroundTang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Morrissey, S. M., Zhang, F., Ding, C., Montoya-Durango, D. E., Hu, X., Yang, C., Wang, Z., Yuan, F., Fox, M., Zhang, H.-G., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.002 · Cited by 605
Self-citationZhang, F., Wang, H., Wang, X., Jiang, G., Liu, H., Zhang, G., Wang, H., Fang, R., Bu, X., Cai, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10561 · Cited by 580 · cited 2×
“Explicitly, TGF-b drives the polarization of TAMs into pro-tumorigenic M2phenotype (110); favors the differentiation of naïve CD4 T cells into Treg cells (111); impairs effector CD8 T cell and NK cell cytotoxicity (112, 113); inhibits DC cell activation (114); and exert inhibitory effects on B cells (115).”
BackgroundUnderstanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
Yamagiwa, S., Gray, J. D., Hashimoto, S., & Horwitz, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7282 · Cited by 538
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice
Singal, A. G., & El-Serag, H. B. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.014 · Cited by 530
Bode, C., Kugler, V., & Bode, J. C. (1987) · Journal of Hepatology · doi:10.1016/s0168-8278(87)80003-x · Cited by 529
Liver sinusoidal endothelial cells — gatekeepers of hepatic immunity
Shetty, S., Lalor, P. F., & Adams, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0020-y · Cited by 523 · cited 1×
“LSECs not only motivate Treg cell activation via TGF-b but also highly express PD-L1 (87).”
BackgroundKlysz, D., Tai, X., Robert, P. A., Craveiro, M., Cretenet, G., Oburoglu, L., Mongellaz, C., Floess, S., Fritz, V., Matias, M. I., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab2610 · Cited by 522
Glutathione primes t cell metabolism for inflammation
Mak, T. W., Grusdat, M., Duncan, G. S., Dostert, C., Nonnenmacher, Y., Cox, M., Binsfeld, C., Hao, Z., Brüstle, A., Itsumi, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.019 · Cited by 511
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496 · cited 1×
“Notably, TIM3 is highly expressed in less differentiated tumor cells (101), which predicts poor prognosis in HBV-associated HCC (102).”
BackgroundPrima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
The Intersection between Tumor Angiogenesis and Immune Suppression
Rahma, O. E., & Hodi, F. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1543 · Cited by 472
Shi, F., Shi, M., Zeng, Z., Qi, R., Liu, Z., Zhang, J., Yang, Y., Tien, P., & Wang, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.25397 · Cited by 464
Metabolic and epigenetic regulation of T-cell exhaustion
Franco, F., Jaccard, A., Romero, P., Yu, Y.-R., & Ho, P.-C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 455
Yeung, O. W. H., Lo, C.-M., Ling, C.-C., Qi, X., Geng, W., Li, C.-X., Ng, K. T. P., Forbes, S. J., Guan, X.-Y., Poon, R. T. P., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.029 · Cited by 453
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448 · cited 1×
“Hypoxia-inducible factor 1a (HIF-1a) mediates ENTPD2 overexpression to convert ATP to 5’-AMP, which recruits a great quantity of MDSCs into the TME (40).”
BackgroundTargeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H., Mancham, S., Pedroza-Gonzalez, A., Polak, W. G., de Jonge, J., Gaspersz, M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B., Weichselbaum, R. R., & Fu, Y.-X. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192282 · Cited by 409
Palmieri, E. M., Menga, A., Martín-Pérez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D. C., Lamers, W. H., Ghesquière, B., McVicar, D. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.054 · Cited by 404
Liver inflammation abrogates immunological tolerance induced by Kupffer cells
Heymann, F., Peusquens, J., Ludwig‐Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., Martin, C., van Rooijen, N., Ochando, J. C., Randolph, G. J., et al. (2015) · Hepatology · doi:10.1002/hep.27793 · Cited by 398
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Cham, C. M., Driessens, G., O'Keefe, J. P., & Gajewski, T. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200838289 · Cited by 388
Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge
Knoll, P., Schlaak, J., Uhrig, A., Kempf, P., zum Büschenfelde, K.-H. M., & Gerken, G. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80433-1 · Cited by 384
Wu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
Modulating the microbiome to improve therapeutic response in cancer
McQuade, J. L., Daniel, C. R., Helmink, B. A., & Wargo, J. A. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30952-5 · Cited by 376
Layered defense: how mucus and tight junctions seal the intestinal barrier
Capaldo, C. T., Powell, D. N., & Kalman, D. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1557-x · Cited by 372
Glucose Availability Regulates IFN-γ Production and p70S6 Kinase Activation in CD8+ Effector T Cells
Cham, C. M., & Gajewski, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4670 · Cited by 359
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Flecken, T., Schmidt, N., Hild, S., Gostick, E., Drognitz, O., Zeiser, R., Schemmer, P., Bruns, H., Eiermann, T., Price, D. A., et al. (2014) · Hepatology · doi:10.1002/hep.26731 · Cited by 351
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
Jiang, R., Tang, J., Chen, Y., Deng, L., Ji, J., Xie, Y., Wang, K., Jia, W., Chu, W.-M., & Sun, B. (2017) · Nature Communications · doi:10.1038/ncomms15129 · Cited by 343
Th17 Cells in Cancer: The Ultimate Identity Crisis
Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 334
γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Daley, D., Zambirinis, C. P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V. R. K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.046 · Cited by 329
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice
Ferrere, G., Wrzosek, L., Cailleux, F., Turpin, W., Puchois, V., Spatz, M., Ciocan, D., Rainteau, D., Humbert, L., Hugot, C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.008 · Cited by 324
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
Ren, D., Hua, Y., Yu, B., Ye, X., He, Z., Li, C., Wang, J., Mo, Y., Wei, X., Chen, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1144-6 · Cited by 316
Yang, Y., Ye, Y.-C., Chen, Y., Zhao, J.-L., Gao, C.-C., Han, H., Liu, W.-C., & Qin, H.-Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0818-0 · Cited by 307
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Yan, W., Liu, X., Ma, H., Zhang, H., Song, X., Gao, L., Liang, X., & Ma, C. (2015) · Gut · doi:10.1136/gutjnl-2014-307671 · Cited by 306
Gut microbiota-derived propionate reduces cancer cell proliferation in the liver
Bindels, L. B., Porporato, P., Dewulf, E. M., Verrax, J., Neyrinck, A. M., Martin, J. C., Scott, K. P., Buc Calderon, P., Feron, O., Muccioli, G. G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.409 · Cited by 305
The TNF Paradox in Cancer Progression and Immunotherapy
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01818 · Cited by 305
Natural killer cells in liver disease
Tian, Z., Chen, Y., & Gao, B. (2013) · Hepatology · doi:10.1002/hep.26115 · Cited by 290
Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286 · cited 1×
“Under persistent hypoxia, HIF-1a/IL-1b loop between tumor cells and TAMs fosters epithelial-mesenchymal transition (EMT) and immune evasion (68).”
BackgroundLactate supports a metabolic-epigenetic link in macrophage polarization
Noe, J. T., Rendon, B. E., Geller, A. E., Conroy, L. R., Morrissey, S. M., Young, L. E. A., Bruntz, R. C., Kim, E. J., Wise-Mitchell, A., Barbosa de Souza Rizzo, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8602 · Cited by 283
Zhang, H.-L., Yu, L.-X., Yang, W., Tang, L., Lin, Y., Wu, H., Zhai, B., Tan, Y.-X., Shan, L., Liu, Q., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.011 · Cited by 281
Ye, L.-Y., Chen, W., Bai, X.-L., Xu, X.-Y., Zhang, Q., Xia, X.-F., Sun, X., Li, G.-G., Hu, Q.-D., Fu, Q.-H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0977 · Cited by 275
Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T. (2015) · OncoImmunology · doi:10.4161/21624011.2014.954829 · Cited by 274
Kalathil, S., Lugade, A. A., Miller, A., Iyer, R., & Thanavala, Y. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 271
Kuang, D.-M., Peng, C., Zhao, Q., Wu, Y., Chen, M.-S., & Zheng, L. (2010) · Hepatology · doi:10.1002/hep.23291 · Cited by 263
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 257
Zhou, J., Ding, T., Pan, W., Zhu, L., Li, L., & Zheng, L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24556 · Cited by 256
Telesford, K. M., Yan, W., Ochoa-Reparaz, J., Pant, A., Kircher, C., Christy, M. A., Begum-Haque, S., Kasper, D. L., & Kasper, L. H. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1056973 · Cited by 252
Arihara, F., Mizukoshi, E., Kitahara, M., Takata, Y., Arai, K., Yamashita, T., Nakamoto, Y., & Kaneko, S. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1447-1 · Cited by 252
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241 · cited 1×
“Hypoxemia is a key regulatory factor that induces MDSCs accumulation via the chemokine C-C motif Ligand 26 (CCL26)/CX3CR1 pathway (39).”
BackgroundChen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., & Zheng, S.-S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024671 · Cited by 240
Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma
Hung, M. H., Lee, J. S., Ma, C., Diggs, L. P., Heinrich, S., Chang, C. W., Ma, L., Forgues, M., Budhu, A., Chaisaingmongkol, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21804-1 · Cited by 238
The Treg/Th17 Cell Balance: A New Paradigm for Autoimmunity
Eisenstein, E. M., & Williams, C. B. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819e76c7 · Cited by 231
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4012 · Cited by 229
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
Gautron, A., Dominguez‐Villar, M., de Marcken, M., & Hafler, D. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201344392 · Cited by 228
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Ahmadzadeh, M., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5215 · Cited by 225
Keenan, B. P., Fong, L., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
Wong, V. W., Yu, J., Cheng, A. S., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K., Chan, F. K., Sung, J. J., & Chan, H. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24281 · Cited by 208
Dong, P., Ma, L., Liu, L., Zhao, G., Zhang, S., Dong, L., Xue, R., & Chen, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030320 · Cited by 207
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Limagne, E., Richard, C., Thibaudin, M., Fumet, J.-D., Truntzer, C., Lagrange, A., Favier, L., Coudert, B., & Ghiringhelli, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1564505 · Cited by 201
Mengshol, J. A., Golden-Mason, L., Arikawa, T., Smith, M., Niki, T., McWilliams, R., Randall, J. A., McMahan, R., Zimmerman, M. A., Rangachari, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009504 · Cited by 196
Chen, T., Li, Q., Wu, J., Wu, Y., Peng, W., Li, H., Wang, J., Tang, X., Peng, Y., & Fu, X. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2233-x · Cited by 195
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Kudo, M. (2017) · Oncology · doi:10.1159/000451016 · Cited by 194
Hou, J., Zhang, H., Sun, B., & Karin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.014 · Cited by 193
Deng, Y., Cheng, J., Fu, B., Liu, W., Chen, G., Zhang, Q., & Yang, Y. (2017) · Oncogene · doi:10.1038/onc.2016.273 · Cited by 186
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 185
El-Nezami, H. S., Polychronaki, N. N., Ma, J., Zhu, H., Ling, W., Salminen, E. K., Juvonen, R. O., Salminen, S. J., Poussa, T., & Mykkänen, H. M. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.5.1199 · Cited by 184
Jian, S.-L., Chen, W.-W., Su, Y.-C., Su, Y.-W., Chuang, T.-H., Hsu, S.-C., & Huang, L.-R. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.192 · Cited by 183
Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer
Fotiadis, C. I., Stoidis, C. N., Spyropoulos, B. G., & Zografos, E. D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6453 · Cited by 180
Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1
Gur, C., Maalouf, N., Shhadeh, A., Berhani, O., Singer, B. B., Bachrach, G., & Mandelboim, O. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581531 · Cited by 180
Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases
Toor, D., Wsson, M. K., Kumar, P., Karthikeyan, G., Kaushik, N. K., Goel, C., Singh, S., Kumar, A., & Prakash, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102432 · Cited by 177
Liu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 176
Reinforce the antitumor activity of CD 8+ T cells via glutamine restriction
Nabe, S., Yamada, T., Suzuki, J., Toriyama, K., Yasuoka, T., Kuwahara, M., Shiraishi, A., Takenaka, K., Yasukawa, M., & Yamashita, M. (2018) · Cancer Science · doi:10.1111/cas.13827 · Cited by 175
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
Ao, J.-Y., Zhu, X.-D., Chai, Z.-T., Cai, H., Zhang, Y.-Y., Zhang, K.-Z., Kong, L.-Q., Zhang, N., Ye, B.-G., Ma, D.-N., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0866 · Cited by 171
Ohkusa, T., Yoshida, T., Sato, N., Watanabe, S., Tajiri, H., & Okayasu, I. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.005801-0 · Cited by 167
Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma
Yang, X. H., Yamagiwa, S., Ichida, T., Matsuda, Y., Sugahara, S., Watanabe, H., Sato, Y., Abo, T., Horwitz, D. A., & Aoyagi, Y. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.036 · Cited by 164
Alexander, A. A. Z., Maniar, A., Cummings, J.-S., Hebbeler, A. M., Schulze, D. H., Gastman, B. R., Pauza, C. D., Strome, S. E., & Chapoval, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4912 · Cited by 162
Feun, L. G., Li, Y., Wu, C., Wangpaichitr, M., Jones, P. D., Richman, S. P., Madrazo, B., Kwon, D., Garcia‐Buitrago, M., Martin, P., et al. (2019) · Cancer · doi:10.1002/cncr.32339 · Cited by 160
Ketogenic diet in cancer therapy
Weber, D. D., Aminazdeh-Gohari, S., & Kofler, B. (2018) · Aging · doi:10.18632/aging.101382 · Cited by 156
How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions
Bruger, A. M., Dorhoi, A., Esendağlı, G., Barczyk‐Kahlert, K., van der Bruggen, P., Lipoldová, M., Perečko, T., Santibanez, J. F., Saraiva, M., Ginderachter, J. A. V., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2170-8 · Cited by 150
Chau, G., Wu, C.-W., Lui, W., Chang, T.-J., Kao, H.-L., Wu, L., King, K., Loong, C., Hsia, C.-Y., & Chi, C. (2000) · Annals of Surgery · doi:10.1097/00000658-200004000-00015 · Cited by 149
Chronically inflamed livers up-regulate expression of inhibitory B7 family members #
Kassel, R., Cruise, M. W., Iezzoni, J. C., Taylor, N. A., Pruett, T. L., & Hahn, Y. S. (2009) · Hepatology · doi:10.1002/hep.23173 · Cited by 148
Höchst, B., Schildberg, F. A., Sauerborn, P., Gäbel, Y. A., Gevensleben, H., Goltz, D., Heukamp, L. C., Türler, A., Ballmaier, M., Gieseke, F., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.033 · Cited by 147
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Yarchoan, M., Xing, D., Luan, L., Xu, H., Sharma, R. B., Popovic, A., Pawlik, T. M., Kim, A. K., Zhu, Q., Jaffee, E. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0950 · Cited by 145
Dunham, R. M., Thapa, M., Velazquez, V. M., Elrod, E. J., Denning, T. L., Pulendran, B., & Grakoui, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201937 · Cited by 144
Tu, J.-F., Ding, Y.-H., Ying, X.-H., Wu, F.-Z., Zhou, X.-M., Zhang, D.-K., Zou, H., & Ji, J.-S. (2016) · Scientific Reports · doi:10.1038/srep35056 · Cited by 144
Self-citationBajaj, J. S., Kakiyama, G., Savidge, T., Takei, H., Kassam, Z. A., Fagan, A., Gavis, E. A., Pandak, W. M., Nittono, H., Hylemon, P. B., et al. (2018) · Hepatology · doi:10.1002/hep.30037 · Cited by 144
Huang, W., Chen, Z., Zhang, L., Tian, D., Wang, D. W., Fan, D., Wu, K., & Xia, L. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.058 · Cited by 143
Tarao, K., So, K., Moroi, T., Ikeuchi, T., Suyama, T. L., Endo, O., & Fukushima, K. (1977) · Gastroenterology · doi:10.1016/s0016-5085(19)32137-7 · Cited by 143
Lu, T., & Gabrilovich, D. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2939 · Cited by 142
Yang, W., Lu, Y. Z., Xu, Y., Xu, L., Zheng, W., Wu, Y., Li, L., & Shen, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348763 · Cited by 139
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Chen, C., Wang, Z., Ding, Y., & Qin, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-10
- Volume
- 14
- Pages
- 1133308-1133308
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4319984455
- Cited by
- 305
- References
- 295
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.